Intratumoral Injection of α-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
This study describes a novel cancer immunotherapy treatment that exploits the natural anti-Gal Ab to destroy tumor lesions and convert them into an endogenous vaccine targeted to APC via FcγR. Anti-Gal constitutes 1% of immunoglobulins in humans and interacts specifically with α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R). The binding of anti-Gal to α-gal epitopes on pig cells mediates xenograft rejection. The proposed method uses glycolipid micelles with multiple α-gal epitopes (α-gal glycolipids). These glycolipids are extracted from rabbit red cell membranes and are comprised of ceramides with carbohydrate chains containing 5–25 carbohydrates, all capped with α-gal epitopes. Efficacy of this treatment was demonstrated in α1,3-galactosyltransferase knockout mice producing anti-Gal and bearing B16 melanoma or B16/OVA producing OVA as a surrogate tumor Ag. These mice are unique among nonprimate mammals in that, similar to humans, they lack α-gal epitopes and can produce the anti-Gal Ab. Intratumoral injection of α-gal glycolipids results in local inflammation mediated by anti-Gal binding to the multiple α-gal epitopes and activation of complement. These glycolipids spontaneously insert into tumor cell membranes. The binding of anti-Gal to α-gal expressing tumor cells induces the destruction of treated lesions as in anti-Gal-mediated xenograft rejection. Anti-Gal further opsonizes tumor cells within the lesion and, thus, targets them for effective uptake by APC that transport the tumor Ags to draining lymph nodes. APC further cross-present immunogenic tumor Ag peptides and elicit a systemic anti-tumor immune response. Similar intratumoral injection of α-gal glycolipids in humans is likely to induce the destruction of treated lesions and elicit a protective immune response against micrometastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 10×
“on MHC class I and by the OVA323–339 peptide presented on MHC class II (1).”
BackgroundMethodInfluentialThall, A. D., Malý, P., & Lowe, J. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21437 · Cited by 401 · cited 2×
“We tested this hypothesis in 1,3-galactosyltransferase ( 1,3GT) knockout (KO) mice (30), which are the only nonprimate mammals capable of producing anti-Gal because they lack -gal epitopes (30–32).”
MethodInduction of potent antitumor immunity by in situ targeting of intratumoral DCs
Furumoto, K., Soares, L., Engleman, E. G., & Merad, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419762 · Cited by 180
Cited by
Macher, B. A., & Galili, U. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.11.003 · Cited by 404
Self-citationAnti‐Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits
Galili, U. (2013) · Immunology · doi:10.1111/imm.12110 · Cited by 225
Self-citationHuman Anti-Gal and Anti-Non-Gal Immune Response to Porcine Tissue Implants
Galili, U. (2015) · Host Response to Biomaterials · doi:10.1016/b978-0-12-800196-7.00010-4 · Cited by 12
Self-citation
Metadata
- Authors
- Galili, U., Wigglesworth, K., & Abdel-Motal, U. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04-01
- Volume
- 178
- Issue
- 7
- Pages
- 4676-4687
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1484684784
- Cited by
- 71
- References
- 5
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.